Mediwound (MDWD) has released an update.
MediWound Ltd. has secured a €16.25 million funding boost from the European Innovation Council Accelerator Program to fast-track the development of EscharEx, their promising treatment for diabetic foot ulcers. This substantial investment is set to advance the drug’s market launch by four years, highlighting the treatment’s potential to significantly impact patient care for a condition affecting millions. The funding encompasses a grant and an investment, with the latter’s terms under finalization, and underscores MediWound’s commitment to innovate in the field of non-surgical tissue repair and wound debridement.
For further insights into MDWD stock, check out TipRanks’ Stock Analysis page.
